With Enemies Like These: Will the Democrats Make Part D More Pharma Friendly?
This article was originally published in RPM Report
The Democratic leadership rammed a major health bill through the House this summer, including some Medicare Part D fixes that read like a Big Pharma wish list. Have the industry's toughest critics gone soft?
You may also be interested in...
Putting the Dough in the Donut Hole: Big Pharma Hits the Sweet Spot in the Reform Debate
It's not often than any industry group voluntarily agrees to give up $80 billion in future revenues, but that's what the Pharmaceutical Research & Manufacturers of America is pledging to do to in the context of the health care reform debate. There are a lot of details to work out, but this is a case where what is important is not what PhRMA is giving-but what it gets.
Dollars for Donuts: Inside the Key Elements of PhRMA's Health Reform Deal
The key part of PhRMA's deal with the Finance Committee is a double win for industry: assuring that closing the donut hole will be part of reform, and that PhRMA will get credit for a big part of the savings.
Medicare Advantage: Is It Strong Enough To Survive Obama Reform?
Medicare Advantage programs are in the crosshairs of Obama health care reform. The new president has singled out the full-service plans reconstituted under Part D as a major source for the down payment funds for comprehensive health care reform: well over a quarter of the funds for the new system would come from cuts in government payments to Medicare Advantage programs. The situation looks bad for MA plans, but it may be early to write them off. They are strong after five good years of growth.